Literature DB >> 1589400

Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo.

G Golomb1, A Schlossman, H Saadeh, M Levi, J M Van Gelder, E Breuer.   

Abstract

Some geminal bisphosphonates are used clinically for a number of important bone/calcium related diseases; however, side effects and lack of selectivity impede their wide use. This work reports the synthesis and evaluation of bisacylphosphonates (e.g., adipoyl- and suberoylbisphosphonate). These compounds were found to inhibit significantly hydroxyapatite formation and dissolution in vitro and the calcification of bioprosthetic tissue implanted subdermally in rats. These are the first instances of nongeminal bisphosphonates [P-(C)n-P, n greater than or equal to 2] that have been reported to be active in calcium-related disorders. The reported bisacylphosphonates possess apparent lower toxicity, and their calcium complexes/salts have improved solubility properties. Therefore, they are of potential importance for clinical applications.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1589400     DOI： 10.1023/a:1018956516640

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


  16 in total

1.  The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo.

Authors:  H A Fleisch; R G Russell; S Bisaz; R C Mühlbauer; D A Williams
Journal:  Eur J Clin Invest       Date:  1970-03       Impact factor: 4.686

2.  The inhibition of calcium hydroxypatite crystal growth by polyphosphonates and polyphosphates.

Authors:  M D Francis
Journal:  Calcif Tissue Res       Date:  1969

3.  Controlled release of diphosphonates from synthetic polymers to inhibit calcification.

Authors:  G Golomb
Journal:  J Biomater Appl       Date:  1987-10       Impact factor: 2.646

Review 4.  Bone resorption and turnover in health and disease.

Authors:  G R Mundy
Journal:  Bone       Date:  1987       Impact factor: 4.398

Review 5.  Biomaterial-associated calcification: pathology, mechanisms, and strategies for prevention.

Authors:  F J Schoen; H Harasaki; K M Kim; H C Anderson; R J Levy
Journal:  J Biomed Mater Res       Date:  1988-04

6.  Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating.

Authors:  G Golomb; M Dixon; M S Smith; F J Schoen; R J Levy
Journal:  J Pharm Sci       Date:  1987-04       Impact factor: 3.534

Review 7.  Bisphosphonates--history and experimental basis.

Authors:  H Fleisch
Journal:  Bone       Date:  1987       Impact factor: 4.398

8.  Prevention of bioprosthetic heart valve tissue calcification by charge modification: effects of protamine binding by formaldehyde.

Authors:  G Golomb; V Ezra
Journal:  J Biomed Mater Res       Date:  1991-01

9.  Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo.

Authors:  M D Francis; R G Russell; H Fleisch
Journal:  Science       Date:  1969-09-19       Impact factor: 47.728

10.  Inhibition by diphosphonate compounds of calcification of porcine bioprosthetic heart valve cusps implanted subcutaneously in rats.

Authors:  R J Levy; M A Hawley; F J Schoen; S A Lund; P Y Liu
Journal:  Circulation       Date:  1985-02       Impact factor: 29.690
View more
  8 in total

1.  Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.

Authors:  H Cohen; V Solomon; I S Alferiev; E Breuer; A Ornoy; N Patlas; N Eidelman; G Hägele; G Golomb
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

2.  The effect of heparin hydrogel embedding on glutaraldehyde fixed bovine pericardial tissues: Mechanical behavior and anticalcification potential.

Authors:  Adel Badria; Petros Koutsoukos; Sotirios Korossis; Dimosthenis Mavrilas
Journal:  J Mater Sci Mater Med       Date:  2018-11-09       Impact factor: 3.896

3.  Biomimetic coating of bisphosphonate incorporated CDHA on Ti6Al4V.

Authors:  Huan Zhou; Joseph G Lawrence; Ahmed H Touny; Sarit B Bhaduri
Journal:  J Mater Sci Mater Med       Date:  2011-12-17       Impact factor: 3.896

4.  Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.

Authors:  H Cohen; I S Alferiev; J Mönkkönen; M J Seibel; T Pinto; A Ezra; V Solomon; D Stepensky; H Sagi; A Ornoy; N Patlas; G Hägele; A Hoffman; E Breuer; G Golomb
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

5.  In vitro inhibition of membrane-mediated calcification by novel phosphonates.

Authors:  D Skrtic; N Eidelman; G Golomb; E Breuer; E D Eanes
Journal:  Calcif Tissue Int       Date:  1996-05       Impact factor: 4.333

6.  A new route of drug administration: intrauterine delivery of insulin and calcitonin.

Authors:  G Golomb; A Avramoff; A Hoffman
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

7.  Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption.

Authors:  G Golomb; Y Eitan; A Hoffman
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

Review 8.  Biomimetic Mineralization of Biomaterials Using Simulated Body Fluids for Bone Tissue Engineering and Regenerative Medicine<sup/>.

Authors:  Kyungsup Shin; Timothy Acri; Sean Geary; Aliasger K Salem
Journal:  Tissue Eng Part A       Date:  2017-05-22       Impact factor: 4.080
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.